Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Oncogenic FIP1L1-PDGFR-alpha signaling: influence of subcellular localisation and unconventional STAT activation

ABSTRACT: Aberrant activation of oncogenic kinases is frequently observed in human cancers, but the underlying mechanism and resulting effects on global signaling are incompletely understood. Here, we demonstrate that the oncogenic FIP1L1-PDGFRa kinase exhibits a significantly different signaling pattern compared to PDGFRa wildtype: Interestingly, the conventional strong activation of PI3-kinase- and MAP-kinase- pathways is remarkably shifted towards a prominent activation of STAT factors. This diverging signaling pattern compared to classical PDGF-receptor signaling is partially coupled to the aberrant intracellular location of the oncogene, since membrane targeting of F/PDGFRa restores activation of MAPK- and PI3K-pathway completely. In contrast to the M-^SclassicalM-^T cytokine-induced STAT-activation process does STAT activation by F/PDGFR not require Janus kinase activity and does not involve a SH2-domain-mediated binding mechanism. Thus it is conceivable that STAT activation by F/PDGFR could be directly mediated by interaction of STAT factors with the kinase domain itself.

ORGANISM(S): Homo sapiens

SUBMITTER: Arnaud Muller

PROVIDER: E-MTAB-2102 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Similar Datasets

Project description:The outcome for children with high-grade gliomas (HGG) remains dismal, with a two-year survival rate of only 10-30%. Approximately half of pediatric HGGs are diffuse intrinsic pontine glioma (DIPG), a brainstem tumor that arises almost exclusively in children. Genome-wide analyses of copy number imbalances previously showed that platelet derived growth factor receptor alpha (PDGFRA) is the most frequent target of focal amplification in pediatric HGGs. To determine whether the PDGFRA is also targeted by more subtle mutations not detected by copy number analysis, we sequenced all PDGFRA coding exons from a cohort of pediatric HGGs. Somatic activating mutations were identified in 14.4% (13/90) of non-brainstem pediatric HGGs and 4.7% (2/43) of DIPGs, including missense mutations and in-frame deletions and insertions not previously described. 40% of tumors with mutation showed concurrent amplification, while 60% carried heterozygous mutations. Six different mutations impacting different domains all resulted in ligand-independent receptor activation that was blocked by small molecule inhibitors of PDGFR. Expression of mutants in p53-null primary mouse astrocytes conferred a proliferative advantage in vitro, and generated HGGs in vivo with complete penetrance when implanted into brain. The gene expression signatures reflected the spectrum of human diffuse HGGs. PDGFRA intragenic deletion of exons 8 and 9 were previously shown in adult HGG, but were not detected in 83 non-brainstem pediatric HGG and 57 DIPGs. Thus, a distinct spectrum of mutations confers constitutive receptor activation and oncogenic activity to PDGFR in childhood HGG. To better understand the consequence of PDGFRα mutation in pediatric gliomagenesis, retroviral constructs expressing wild-type PDGFRα or six selected PDGFRα mutants that affect different regions of the receptor were generated for functional studies. p53-null primary mouse astrocyte (PMA) cultures were chosen as a relevant cellular background to assess PDGFRα function.

Dataset Information

Oncogenic FIP1L1-PDGFR-alpha signaling: influence of subcellular localisation and unconventional STAT activation

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets